Richard L Md Lindstrom bought $461K of Ocular Therapeutix (OCUL)
Executed Feb 20, disclosed Feb 24, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 24), the stock returned -4.1% (delay-adjusted); from the execution session (Feb 20), +17.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Richard L Md Lindstrom (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in Ocular Therapeutix, Inc. (OCUL). Across 1 priced purchase filing, the average 21-session return was +17.0% from execution and -4.1% from disclosure (delay-adjusted; derived). The largest single filing was $461K of OCUL (60,229 sh × $7.66, as filed), executed Feb 20.
Healthcare · Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases a…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→